

Document number	r: TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 <u>2024</u>

1.0 Introduction

As a requirement, under Article 5.4.1 of the 2021 World Anti-Doping Code (Code); "Anti-Doping Organizations shall conduct test distribution planning and Testing as required by the International Standard for Testing and Investigations." The International Standard for Testing and Investigations (ISTI) outlines in Article 4.2.3. that: "In developing its Test Distribution Plan, the Anti-Doping Organization shall incorporate the requirements of the TDSSA."

This <u>Technical Document</u> for <u>Sport Specific Analysis (TDSSA)</u> is intended to ensure that the <u>Prohibited Substances</u> and/or <u>Prohibited Methods</u> within the scope of the <u>TDSSA</u> and other tools that support the detection of <u>Prohibited Substances</u> and/or identify the <u>Use</u> of <u>Prohibited Methods</u> such as the <u>Athlete Biological Passport (ABP)</u> are subject to an appropriate and consistent level of use, <u>analysis</u> and adoption by all <u>Anti-Doping Organizations (ADOs)</u> that conduct <u>Testing</u> in those sports or disciplines deemed <u>to be</u> at risk, of <u>doping using the <u>Prohibited Substances and/or Prohibited Methods</u> within the scope of the <u>TDSSA</u>. Compliance with the <u>TDSSA and its Appendices</u> is mandatory under the <u>CodelSTI</u>.</u>

The <u>TDSSA</u> complements other anti-doping tools and programs such as the *ABP*, intelligence gathering and investigations. The development of the <u>TDSSA</u> is based on a scientific approach, linking physiological and non-physiological demands of *Athlete* performance with the potential ergogenic benefit of those *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u>.

A Minimum Level of Analysis (MLA) is specified for the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u> for each sport or discipline, expressed as a percentage of the total number of eligible <u>Tests</u> and based on a Physiological Risk Assessment of that sport or discipline. The full MLA list for each sport or discipline is provided in Appendices 1 and 2 of this *Technical Document* which are also a mandatory component of the TDSSA.

The MLA applies to *Testing* conducted by all *ADOs* on *International-Level Athletes* and *National-Level Athletes* as defined by the applicable *ADO*.

The MLAs for each sport or discipline should not be considered as the precise level of analysis that an *ADO* should implement in that sport or discipline. Instead, and as the name suggests, they should be seen as minimumsminimum requirements, and *ADOs* are encouraged to exceed the MLAs where they believe—it is appropriate to do so, based on their Risk Assessment and any intelligence they may have access to. *ADOs* are also encouraged to take advantage of Article 6.6 of the *Code*, which permits *ADOs* to request Laboratories to analyze *Samples* that have already been reported as negative and have been stored for Further Analysis, for the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the TDSSA.



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

The full *Prohibited List* remains applicable to all sports, including sports that are not covered by the <u>TDSSA</u> and/or for which the MLA is zero (0%). Any *ADO* may, at its own discretion and expense, request a <u>Laboratory</u> to analyze any *Sample* for any one or more of the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u> at any time.

In addition, under Article 6.4.1 of the Code, "<u>Laboratories</u> at their own initiative and expense may analyze Samples for Prohibited Substances and/or Prohibited Methods not included on the standard Sample analysis menu or as requested by the Anti-Doping Organization that initiated and directed Sample collection." This includes those Prohibited Substances and/or Prohibited Methods which are described in the TDSSA.

WADA has developed a non-mandatory supporting document guidelines intended to assist with the implementation and application of the <u>TDSSA</u>. This document is included herein as Supporting Document AThese guidelines can be found on WADA's website but isare not to be considered an appendix of the <u>TDSSA</u> itself, as itthey will be amended from time to time to reflect the ongoing needs of stakeholders and evolving best practicepractices.

Defined terms in the *Code, International Standards* and the <u>TDSSA</u> can be found in Article 10 of the <u>TDSSA</u>.

2.0 Objectives

The objectives of the TDSSA are to contribute to effective *Testing* by:

- **2.1.** Maintaining well-reasoned and proportionate MLAs for those *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u> in particular sports or disciplines;
- **2.2.** Establishing criteria by which all *ADOs* shall apply MLAs within a <u>Test Distribution Plan</u> (TDP) while recognizing the need for flexibility within the diversity of *Code*-compliant antidoping programs;
- **2.3.** Ensuring the <u>TDSSA</u> supports the implementation of the <u>hematological</u> module of the *ABP* to continue to allow for intelligent *Testing* and targeted analysis for erythropoietin receptor agonists (ERAs¹); and

¹ The acronym 'ERAs' is used in this *Technical Document* to describe the substances analyzed according to the applicable *WADA Technical Document* for EPO in force.



Document number:	TDSSA	Version number:	<mark>89</mark> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 <u>2024</u>

2.4. Informing *ADO*s on *Testing* and analysis best practices for those *Prohibited Substances* and/or *Prohibited Methods* within the scope of the TDSSA in particular sports or disciplines.

3.0 Scope

3.1. Level of Athlete

The <u>TDSSA</u> applies to *Testing* conducted on *International-Level Athletes* and *National-Level Athletes* (as defined by International Federations (IFs) and *National Anti-Doping Organizations (NADOs)*, respectively). *ADOs* may also apply the <u>TDSSA</u> to *Recreational* or other *Athletes* within their jurisdiction. Only analyses conducted on *International-Level Athletes* and *National-Level Athletes* will be used to determine whether the applicable <u>TDSSA</u> MLAs have been met. For the purpose of the <u>TDSSA</u>, all *Athletes* competing in *Events* which are under the jurisdiction of a *Major Event Organization (MEO)* will be presumed to beare *International-Level Athletes* or *National-Level Athletes*.

3.2. Prohibited Substances and/or Prohibited Methods² included within the TDSSA

The *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u> are normally not part of a standard *Sample* analysis conducted by <u>Laboratories</u> and require additional analysis methods.

The Prohibited Substances and/or Prohibited Methods within the scope of the TDSSA are:

- Erythropoietin receptor agonists (ERAs) as listed in Section S2.1.1;
- Growth hormone (GH) as listed in Section S2.2.3; and
- Growth hormone releasing factors (GHRFs) including growth hormone-releasing hormone (GHRH) and its analogues, growth hormone secretagogues (GHS) and its mimetics, and growth hormone-releasing peptides (GHRPs) as listed in Section S2.2.4.

Whilst implementation of the GHRFs MLAs has been mandatory since 1 January 2017, the mandatory implementation of the GH MLAs for all sports or disciplines has been postponed until the endocrine module of the ABP is ready for implementation. and will be assessed once the Endocrine Module of the ABP has been operational for at least one year. Implementation

² Contained within the 2023 WADA Prohibited List.



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

of the Endocrine Module³ of the *ABP* for those sports or disciplines for which the MLA of GH is 15% or higher is strongly recommended. For the sports or disciplines with an MLA for GH of 10%, *ADO*s are encouraged to consider the benefits of implementing the Endocrine Module of the *ABP*.

During the period of the GH MLAs postponement:

- ADOs are encouraged to continue their best efforts to conduct GH Testing by prioritizing the higher risk sports or disciplines listed in the <u>TDSSA</u>;
- In situations where a Sample is reported as an Atypical Finding for GH, and/or where
 investigations indicate reliable intelligence on possible GH abuse, ADOs should target
 the Athlete for GH analysis. In addition, ADOs are strongly encouraged to request longterm storage for such Samples for Further Analysis when further technological
 advancements for GH analysis are available; and
- ADOs will not be held accountable under WADA's compliance monitoring program for any failure to meet the relevant GH MLAs.

Information about the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u> and guidance on *Testing* strategies for each *Prohibited Substance* is provided within the <u>TDSSA</u> *Testing* Guides⁴. In addition to the <u>TDSSA</u> *Testing* Guides, a *Testing* Guide on Gas Chromatography/Combustion/Isotope Ratio Mass Spectrometry (GC/C/IRMS) is also available to ADOs.

3.3. Implementation of the Hematological Module of the ABP

The hematological module Hematological Module of the ABP plays an important part in the targeting of Athletes for Testing, the detection of ERAs and prosecution of anti-doping rule violations for Use of blood doping methods. The implementation of the hematological module Hematological Module of the ABP for sports or disciplines with an ERAs MLA of 30% or greater is a mandatory component of compliance with the TDSSA.

³ Please contact WADA's ABP team at athletepassport@wada-ama.org to receive the Frequently Asked Questions (FAQs) document for the Endocrine Module of the ABP for further information on testing strategies.

⁴ Please contact testing@wada-ama.org for a copy of the <u>TDSSA</u> Testing Guides and/or the GC/C/IRMS Testing Guide.



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

In addition, for the purposes of compliance with the TDSSA, the implementation of the hematological module Module of the ABP shall include the following mandatory criteria:

- a) Include all Athletes from those sports or disciplines with an ERAs MLA of 30% or greater (as identified in the <u>TDSSA</u>) that are included in an ADO's <u>TDP</u>, and are part of the ADO's Registered Testing Pool (RTP);
- b) The *ABP* program shall be compliant with all applicable *ABP Technical Documents* and *International Standards*, including the ISTI, the *International Standard* for *Results Management* and the applicable *Technical Document* for *Athlete* Passport Management Units (APMU) in force;
- c) At a minimum, an average of three blood ABP <u>Tests</u> shall be planned annually across all Athletes from those sports or disciplines with an ERAs MLA of 30% or greater, who are part of the RTP of an ADO and therefore part of the ADO's ABP <u>hematological</u> <u>module Hematological Module</u> program; and
- d) The distribution of these <u>Tests</u> shall be carried out according to the status of the <u>Athlete</u>'s <u>Passport</u>, as well as any intelligence the <u>ADO</u> may have access to and the recommendations of the <u>APMU</u>, so that <u>Athletes</u> with atypical/suspicious <u>Passports</u> receive more <u>Tests</u> than those with normal <u>Passports</u>.

ADOs are required to report the details of their RTP to WADA through the Anti-Doping Administration and Management System (ADAMS). An ADO's compliance in relation to its hematological ABP program will be monitored by WADA as part of its wider compliance monitoring program based on the criteria outlined above and as per the ISTI.

As a guide to WADA's assessment of the required number of blood ABP Tests per ADO (see criterion (c) above), the annual number of blood ABP Tests conducted by the ADO and recorded in ADAMS will be divided by the number of Athletes in the RTP from the sports or disciplines with an ERAs MLA of 30% or greater. As an example, if a NADO has 100 Athletes in its RTP, of which 25 are from sports or disciplines with an ERAs MLA of 30% or greater, then the ADO shall focus on these 25 Athletes from sports or disciplines with an ERAs MLA of 30% or greater and plan to conduct a minimum of 75 blood ABP Tests (an average of three Tests x 25 RTP Athletes) during the course of that year.

RTP Athletes with atypical or suspicious <u>Passports</u>, as identified by the <u>APMU</u>, should be subject to greater than three blood <u>ABP Tests</u> during the course of the year. <u>RTP Athletes</u>



Document number	r: TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 <u>2024</u>

with normal⁵ Passports shouldshall have at least one blood ABP Test during the course of the year. For an RTP Athlete from a sport or discipline with an ERAs MLA of 30% or greater with no previous blood ABP Tests, the ADO shall plan to conduct a minimum of three blood ABP Tests within the first year to establish a baseline and then adjust the Testing frequency, in consultation with the ADO's APMU and intelligence to which the ADO may have access to.

These requirements do not prevent the implementation by an *ADO* of the <u>Hematological Module of the ABP hematological module</u> on *Athletes* outside of its *RTP* <u>e.g., of its *Testing* Pool or those in the *RTP* of another *ADO*, and *ADOs* are encouraged to do so where possible.</u>

Implementation of the hematological module Hematological Module of the ABP for those sports or disciplines for which the MLA for ERAs is 15% is **strongly recommended**. For those sports or disciplines with an MLA for ERAs of 10%, ADOs are encouraged to consider the benefits of implementing the hematological module Hematological Module of the ABP. When implementing the hematological module Hematological Module of the ABP for sports or disciplines with an ERAs MLA of 15% or less, ADOs are encouraged to apply the same criteria as outlined in (b) to (d) above.

Implementation of the hematological module Hematological Module of the ABP also enables ADOs to seek a reduction flexibility in the MLA percentage for ERAs, subject to meeting the criteria outlined in Article 6 of the TDSSA.

4.0 MLA for Sports and Disciplines

MLAs for sports and disciplines are located in:

- Appendix 1: Minimum Levels of Analysis for Sports and Disciplines of Olympic, IOC Recognized and Non-Recognized International Federations.
- Appendix 2: Minimum Levels of Analysis for Sports and Disciplines for Athletes with an
 Impairment Impairment for which the International Paralympic Committee
 acts as the International Federation.
- Appendix 3: Minimum Levels of Analysis for Sports and Disciplines for Athletes with an

⁵ As determined by the APMU

⁶ Includes only those non-International Olympic Committee (IOC) recognized sports that are members of the Alliance of Independent Recognized Members of Sport (AIMS).



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

Impairment for which the International Paralympic Committee does not act as the International Federation.

5.0 Test Distribution Planning and MLA Percentages

5.1. Test Distribution Plan

In accordance with Article 4.1.1 of the ISTI, each *ADO* is required to plan and implement intelligent *Testing* on *Athletes* over whom it has authority, which is proportionate to the risk of doping, and that is effective to detect and to deter such practices.

The <u>TDSSA</u> is part of the <u>Risk Assessment</u> and the overall <u>TDP</u> development process. Once a <u>TDP</u> is developed, each *ADO* will be responsible for managing the implementation of the <u>TDSSA</u> throughout their *Testing* year by applying the required MLAs in a targeted manner to defined *Athletes*.

5.2. Applying MLAs to the Test Distribution Plan

The aim is to test the right *Athletes* for the right *Prohibited Substance(s)* and/or *Prohibited Method(s)* at the right time. Once an *ADO* has conducted the required Risk Assessment and assigned <u>Tests</u> to a sport or discipline within its <u>TDP</u>, it shall apply the prescribed MLA percentage to the number of <u>Tests</u> allocated to each sport or discipline to determine the minimum number of analyses required for each *Prohibited Substance*.

For the purposes of this calculation, one <u>Test</u> includes any number of *Samples* that are collected from one *Athlete* during a single <u>Sample Collection Session</u>. For example, a <u>Sample Collection Session</u> in which one urine *Sample*, one blood *ABP Sample* and one dried blood spot *Sample* are collected will count as one <u>Test</u>. Blood *ABP* and/or dried blood spot <u>Tests</u>, conducted in isolation, shall not be included in this calculation.

As a further example in applying the MLA to a <u>TDP</u>, if an *ADO*'s <u>TDP</u> for a sport or discipline consists of 100 <u>Tests</u> and its MLAs are 60% for ERAs, 10% for GH and 10% for GHRFs, then the minimum number of analyses an *ADO* should conduct is as follows:

- 60 ERAs analyses to be conducted in either urine or blood;
- 10 GH analyses in blood (serum); and
- 10 GHRFs analyses in urine

ADOs can request multiple analyses on Samples collected during the same <u>Sample</u> <u>Collection Session</u>. In the example above, the absolute minimum number of <u>Sample</u>



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

<u>Collection Sessions</u> could be 60. This is on the basis that the required number of GH and GHRF analyses is performed on those *Athletes* who are also being tested for ERAs.

The remaining 40 <u>Tests</u> from the 100 <u>Tests</u> would then be subject to either the standard urine analysis or a greater level of <u>TDSSA</u> or other analysis, which *ADO*s are encouraged to do.

Any MLA that does not equal a whole number when applied to total $\underline{\text{Tests}}$ shall be rounded up or down to the nearest whole number. For example, if five $\underline{\text{Tests}}$ are planned in a particular sport or discipline, for which the ERAs MLA is 10%, the ADO will be required to conduct a minimum of one ERAs analysis (i.e. $5 \times 10\% = 0.5$, which is rounded up to 1). Respectively, if four $\underline{\text{Tests}}$ are planned in a particular sport or discipline, for which the GHRFs MLA is 10%, the ADO will not be required to conduct any GHRFs analysis (i.e. $4 \times 10\% = 0.4$, which is rounded down to 0).

Where the *ADO* has intelligence that would lead to a more effective use of one analysis allocated to a sport or discipline on an *Athlete* in a sport or discipline of higher risk, the *ADO* may reallocate that single analysis.

Although compliance with the <u>TDSSA</u> requirements is mandatory⁷, the total number of athletes eligible for testing, the selection of the *Athletes* to be tested, the selection of the *Sample* matrices collected (*i.e.*, urine or blood) and the timing of those <u>Tests</u> and types of analyses applied to collected *Samples* remain at the discretion of the *ADO*.

Achieving the MLAs for the applicable sports or disciplines should be based on quality of *Testing*, and not simply reaching a required number of <u>Tests</u>. Thus, allocations of <u>Tests</u> should be based on intelligence where possible and may include *ABP* information, whereabouts, timing of competition periods, and any other information that may affect the pattern and the timing of *Use* of the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u>.

Further guidance on the implementation of the <u>TDSSA</u> within a <u>TDP</u> can be found in the *WADA* "Guidelines for Implementing an Effective *Testing* Program", the <u>TDSSA</u> *Testing* Guides and the Frequently Asked Questions (FAQs) located in Supporting Document A.

⁷ Except where expressly stated otherwise



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

5.3. Sports and Disciplines with MLAs of five percent (5%)

To increase flexibility and to enable *ADOs* to focus resources on higher risk sports or disciplines, compliance with the <u>TDSSA</u> requirements for sportsports or disciplines with an MLA of 5% is optional. However, *ADOs* are strongly encouraged to continue their best efforts to meet the 5% MLAs for the respective sports or disciplines listed in the <u>TDSSA</u> to maintain deterrence.

5.4. Sports and Disciplines with MLAs of zero percent (0%)

Those sports or disciplines that are determined to be at minimal physiological risk to the abuse of the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u>, and for which the associated MLA is 0%, shall remain subject to *In-Competition* and *Out-of-Competition* standard urine analysis menus.

However, such sports or disciplines may be subject to *Testing* at any time by any *ADO* for those *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u>, especially if the *ADO* gathers specific information relating to potential use of such *Prohibited Substances* and/or *Prohibited Methods*.

6.0 Flexibility in Implementing the MLAs

Article 4.7.2 of the ISTI outlines that: "An Anti-Doping Organization may apply to WADA for flexibility in the implementation of the minimum levels of analysis specified for Prohibited Substances or Prohibited Methods as outlined in the TDSSA."

In order for *WADA* to consider flexibility in the implementation of the MLAs, the *ADO* shall demonstrate its implementation of the hematological module Mematological Module of the *ABP* and/or the implementation of intelligence-led *Testing* strategies and/or tools and how such approaches lead to the most effective and efficient use of the available *Testing* resources. Compliance with the <u>TDSSA</u> alone is not sufficient, to demonstrate intelligence-led testing.

Following the completion of a self-assessment against set criteria, and the submission to *WADA* of relevant documents such as the *ADO*'s Risk Assessment, <u>TDP</u> and *RTP*, an *ADO* will automatically qualify for flexibility in the implementation of the MLAs of up to 50% for the sports or disciplines the *ADO* seeks flexibility for, subject to a review by *WADA*.

⁸ Requests for flexibility in the implementation of the MLAs of more than 50% will not be accepted.



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

WADA withholds the right to request further information from the ADO to justify the requested flexibility. WADA may Sports and disciplines with MLAs of 10% or less are not eligible for flexibility. WADA may deny, withdraw or reduce the level of flexibility if the self-assessment was incorrectly answered or relevant documents requested are partially/not submitted within the requested timelines or arethe ADO's testing program is found not to be compliant with the ISTI. The self-assessment criteria include (but are not limited to) the following:

6.1 Implementation of the Hematological Module of the *ABP* (Applies to the MLA for ERAs only).

To be eligible for flexibility of up to 50% of the ERAs MLAs for sports or disciplines based on the adoption of the hematological.module Module of the ABP, the ADO shall be able to demonstrate that it meets all of the criteria below:

- **6.1.1** The *ABP* program of the sport or discipline has been fully operational for at least 12 months;
- **6.1.2** The ABP program is managed by a WADA-approved APMU in accordance with the applicable Technical Document for APMUs in force.
- 6.1.26.1.3 The ABP program implements Target Testing that acts upon the recommendations of an APMU with reference to ERAs;
- 6.1.36.1.4 All relevant ABP data, including Doping Control forms (DCFs), are available in ADAMS, which permits oversight by WADA; and
- 6.1.46.1.5 All criteria described in Article 3.3 of this *Technical Document* are met; and.
- 6.1.5 The ABP program is managed by a WADA-approved <u>Athlete Passport Management</u>
 <u>Unit (APMU)</u> in accordance with the applicable <u>Technical Document</u> for <u>APMU</u>s in force.

6.2 Non-ABP (Hematological Module) related criteria

Flexibility in implementing the MLAs due to non-ABP related criteria mayapplies only be implemented forto the Prohibited Substances and/or Prohibited Methods within the scope of the TDSSA. Such criteria include (but are not limited to):

a) Prioritization of Target Testing to be the majority of testing for both In-Competition and Out-of-Competition;



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

- b) Collaboration with other ADOs, for example in sharing Testing plans for Athletes of joint interest:
- <u>b) Mechanisms to gather Anti-doping intelligence received is collated and use of such intelligence in the analyzed to establish patterns, trends and relationships that assist in the further development of an effective anti-doping strategy;</u>
- c) The development and implementation of an ADO's anti-doping program, including conducting investigations; policies and procedures for the sharing of information with other ADOs and law enforcement, and for the facilitation and encouragement of confidential sources.
- d) Collaboration with law enforcement authorities;
- e)d) Alternative The implementation of alternative Testing strategies including the application of specific analysis for other *Prohibited Substances* and/or *Prohibited Methods* outside the scope of the TDSSA;, the collection of dried blood spot Samples, the collection of blood Samples for the Steroidal Module of the ABP, the use of the Endocrine Module of the ABP, etc.;
- f)e) Long Regular review of Samples in long-term storage of Samples in line with a documented storage to assess and implement Further Analysis strategy as needed; and
- g) Compliant entry Use of DCFs into ADAMS within 21 days of Sample an electronic system (i.e., "paperless") to conduct sample collection.
- f) Upon sessions (e.g., by utilizing WADA's request, an ADO shallDCO Central application).

<u>ADOs that can</u> demonstrate that the above criteria are actively part of the *ADO's* anti-doping program. will receive a 10% flexibility in the implementation of the MLAs for meeting each criterion from a), d), e) and/or f), whereas, for meeting criteria b) and/or c) ADOs will receive a 5% flexibility for each criterion met.

6.3 Application for Flexibility- in the Implementation of the MLAs

The process and the full list of criteria required to support an application for flexibility in implementing the MLAs can be found in <u>WADA's Code Compliance Center</u> and the <u>Application for Flexibility User Guide</u> on WADA's website.



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

6.4 Period for Flexibility in the Implementation of the MLAs

Flexibility in the implementation of the MLAs will remain valid for a maximum period of two years provided that the *ADO* continues to comply with the list of criteria included in <u>WADA's Code Compliance Center</u> or the <u>Application for Flexibility User Guide</u>. If the *ADO* no longer meets the criteria contained within its application for flexibility, the *ADO* shall notify *WADA*.

Applications for flexibility are Flexibility granted under this Article 6 is subject to review by WADA at any time. Should an ADO wish to extend the validity period of its flexibility, the ADO shall contact WADA in advance of its expiration.

7.0 Documentation

ADOs shall ensure the following information is accurately recorded on the applicable document or in ADAMS to ensure that WADA can monitor and evaluate an ADO's implementation of the TDSSA:

7.1. Sport and Discipline on the DCF

To ensure accurate recording of Sample analysis by the <u>Laboratories</u> and reporting of statistics in ADAMS, <u>Testing Authorities</u>, <u>Sample Collection Authorities</u> and their <u>Doping Control Officers</u> must ensure that the correct sport and discipline for the <u>Athlete</u>, as listed in Appendices 1 and 2 of the <u>TDSSA</u>, is recorded at a minimum on the <u>Laboratory</u> copy of the DCF.

7.2. Type of Analysis for each Sample

The request for analysis of the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u> shall be provided to the <u>Laboratory</u> for each *Sample* to ensure the <u>Laboratory</u> conducts the correct analyses and accurately reports the results in *ADAMS*.

The specific type of analysis required for each *Sample* shall be recorded on the chain of custody (or equivalent) documentation shipped with the *Samples* to the <u>Laboratory</u> or by an otherwise effective communication method that has been agreed with the <u>Laboratory</u> responsible for analyzing an *ADO's Samples*. However, the type of analysis requested shall not be recorded on the DCF.

7.3. Level of Athlete Tested

The <u>TDSSA</u> shall be applicable to *International-Level Athletes* and *National-Level Athletes* as defined by each *ADO*. To assist with the monitoring of an <u>ADOs'ADO's</u> <u>TDP</u> and



Document number	r: TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 <u>2024</u>

compliance with the application of the MLAs to those defined *Athletes*, *ADOs* shall record the level of the *Athlete* in *ADAMS*. *ADOs* may be requested to validate such data to *WADA* as part of *WADA*'s wider compliance program.

8.0 Data Analysis and Monitoring

To monitor compliance, *WADA* utilizes the <u>TDSSA</u> Monitoring tool in *ADAMS* Next Gen. It is strongly recommended that *ADO*s use this tool to monitor their compliance with the <u>TDSSA</u> regularly. For more information on the <u>TDSSA</u> Monitoring tool in *ADAMS* Next Gen, *ADOs* can refer to either the <u>Reporting Guide to Monitor Testing</u> on *WADA's* website or the <u>ADAMS Help Center</u>.

For <u>TDSSA</u> monitoring and compliance purposes, *WADA* will assess whether the *ADO* has complied with the MLAs based on *Doping Control* statistics contained in *ADAMS*. This will include, but not be limited to, the following elements:

- Total number of <u>Tests</u> and types of analyses <u>for the period 1 January 31 December</u>;
- MLA achieved for each *Prohibited Substance* category within the scope of the <u>TDSSA</u> for each sport or discipline listed in the *ADO's* <u>TDP</u>;
- Number of Athletes tested; and
- Implementation of the hematological module Hematological Module of the ABP for sports or disciplines with an ERAs MLA equal to or greater than 30%, for RTP Athletes.

These statistics and any other relevant information will also be used to review and modify the <u>TDSSA</u> over time.

It is expected that *ADOs* will also utilize this data to assist in the review of their <u>TDP</u> and the management of their *Doping Control* programs.

A wider evaluation of *ADOs*' compliance with the <u>TDSSA</u> is being addressed through *WADA*'s continuous compliance and monitoring program. The evaluation includes a review of the methods applied by the *ADOs* to the implementation of the <u>Tests</u> in order to meet the MLAs as outlined in the ISTI, including but not limited to the assessment of risk among *Athletes* within the jurisdiction of the *ADO*, and the use of information and intelligence in the selection and timing of <u>Tests</u> on defined *Athletes*.

As outlined in Section 6, ADOs may apply for flexibility in implementing the MLAs based on their implementation of the hematological module of the ABP and/or use of intelligence-led Testing strategies and other tools that will lead to the most effective and efficient use of available resources.



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

Any retrospective analysis for the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the TDSSA requested by *ADOs* will count towards compliance with the TDSSA requirements of the year that the *Sample* was collected than the year the retrospective analysis is requested.

9.0 Review of TDSSA

As part of an ongoing review process, *WADA* will monitor the implementation of the <u>TDSSA</u>. Revisions to the <u>TDSSA</u> may be issued from time to time based on consultation with *ADOs* and <u>Laboratories</u> or the revision to the *Code* or *International Standards* or for other reasons at *WADA*'s discretion (e.g., revisions to the *Prohibited List* or inclusion of a *Prohibited Substance* and/or *Prohibited Method* that is not within the scope of the <u>TDSSA</u>). *ADOs* will be provided with prior notice of such modifications taking effect.

10.0 Definitions

10.1. Defined Terms from the 2021 Code that are used in the TDSSA are italicized.

ADAMS: The Anti-Doping Administration and Management System is a Web-based database management tool for data entry, storage, sharing, and reporting designed to assist stakeholders and WADA in their anti-doping operations in conjunction with data protection legislation.

Anti-Doping Organization: WADA or a Signatory that is responsible for adopting rules for initiating, implementing or enforcing any part of the Doping Control process. This includes, for example, the International Olympic Committee, the International Paralympic Committee, other Major Event Organizations that conduct Testing at their Events, International Federations, and National Anti-Doping Organizations.

Athlete: Any Person who competes in sport at the international level (as defined by each International Federation) or the national level (as defined by each National Anti-Doping Organization). An Anti-Doping Organization has discretion to apply anti-doping rules to an Athlete who is neither an International-Level Athlete nor a National-Level Athlete, and thus to bring them within the definition of "Athlete". In relation to Athletes who are neither International-Level nor National-Level Athletes, an Anti-Doping Organization may elect to: conduct limited Testing or no Testing at all; analyze Samples for less than the full menu of Prohibited Substances; require limited or no whereabouts information; or not require advance TUEs. However, if an Article 2.1, 2.3 or 2.5 anti-doping rule violation is committed by any Athlete over whom an Anti-Doping Organization has elected to exercise its authority to test and who competes below the international or national level, then the Consequences set forth in the Code must be applied. For purposes of Article 2.8 and Article 2.9 and for purposes of anti-doping information and Education, any Person who participates

TDSSA, Version 9.0 — 1 Jan 2028 Page 14/30



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 <u>2024</u>

in sport under the authority of any Signatory, government, or other sports organization accepting the Code is an Athlete.

[Comment to Athlete: Individuals who participate in sport may fall in one of five categories: 1) International-Level Athlete, 2) National-Level Athlete, 3) individuals who are not International or National-Level Athletes but over whom the International Federation or National Anti-Doping Organization has chosen to exercise authority, 4) Recreational Athlete, and 5) individuals over whom no International Federation or National Anti-Doping Organization has, or has chosen to, exercise authority. All International and National-Level Athletes are subject to the anti-doping rules of the Code, with the precise definitions of international and national-level sport to be set forth in the anti-doping rules of the International Federations and National Anti-Doping Organizations]

Athlete Biological Passport: The program and methods of gathering and collating data as described in the International Standard for Testing and Investigations and International Standard for Laboratories.

Code: The World Anti-Doping Code.

Deping Control: All steps and processes from test distribution planning through to ultimate disposition of any appeal and the enforcement of *Consequences*, including all steps and processes in between, including but not limited to, *Testing*, investigation, whereabouts, *TUEs*, *Sample* collection and handling, laboratory analysis, *Results Management* and investigations or proceedings relating to violations of <u>Article 10.14</u> (Status During *Ineligibility* or *Provisional Suspension*).

Event: A series of individual Competitions conducted together under one ruling body (e.g., the Olympic Games, World Championships of an International Federation, or Pan American Games).

Event Period: The time between the beginning and end of an **Event**, as established by the ruling body of the **Event**.

In-Competition: The period commencing at 11:59 p.m. on the day before a *Competition* in which the *Athlete* is scheduled to participate through the end of such *Competition* and the *Sample* collection process related to such *Competition*. Provided, however, *WADA* may approve, for a particular sport, an alternative definition if an International Federation provides a compelling justification that a different definition is necessary for its sport; upon such approval by *WADA*, the alternative definition shall be followed by all *Major Event Organizations* for that particular sport.

[Comment to In-Competition: Having a universally accepted definition for In-Competition provides greater harmonization among Athletes across all sports, eliminates or reduces confusion among



Document number:	TDSSA	Version number:	<mark>89</mark> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

Athletes about the relevant timeframe for In-Competition Testing, avoids inadvertent Adverse Analytical Findings in between Competitions during an Event and assists in preventing any potential performance enhancement benefits from Substances prohibited Out-of-Competition being carried over to the Competition period.]

International-Level Athlete: Athletes who compete in sport at the international level, as defined by each International Federation, consistent with the International Standard for Testing and Investigations.

[Comment to International-Level Athlete: Consistent with the International Standard for Testing and Investigations, the International Federation is free to determine the criteria it will use to classify Athletes as International-Level Athletes, e.g., by ranking, by participation in particular International Events, by type of license, etc. However, it must publish those-criteria in clear and concise form, so that Athletes are able to ascertain quickly and easily when they will become classified as International-Level Athletes. For example, if the criteria include participation in certain International Events, then the International Federation must publish a list of those International Events.]

International Standard: A standard adopted by WADA in support of the Code. Compliance with an International Standard (as opposed to another alternative standard, practice or procedure) shall be sufficient to conclude that the procedures addressed by the International Standard were performed properly. International Standards shall include any Technical Documents issued pursuant to the International Standard.

Major Event Organizations: The continental associations of *National Olympic Committees* and other international multisport organizations that function as the ruling body for any continental, regional or other International *Event*.

National Anti-Doping Organization: The entity(ies) designated by each country as possessing the primary authority and responsibility to adopt and implement anti-doping rules, direct the collection of Samples, manage test results and conduct Results Management at the national level. If this designation has not been made by the competent public authority(ies), the entity shall be the country's National Olympic Committee or its designee.

National-Level Athlete: Athletes who compete in sport at the national level, as defined by each National Anti-Doping Organization, consistent with the International Standard for Testing and Investigations.

Out-of-Competition: Any period which is not In-Competition.

Prohibited List: The List identifying the Prohibited Substances and Prohibited Methods.



Document number:	TDSSA	Version number:	<mark>89</mark> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 2022 16 November 2023	Effective date:	1 January 2023 2024

Prohibited Substance: Any substance, or class of substances, so described on the Prohibited List.

Recreational Athlete: A natural Person who is so defined by the relevant National Anti-Doping Organization; provided, however, the term shall not include any Person who, within the five (5) years prior to committing any anti-doping rule violation, has been an International-Level Athlete (as defined by each International Federation consistent with the International Standard for Testing and Investigations) or National-Level Athlete (as defined by each National Anti-Doping Organization consistent with the International Standard for Testing and Investigations), has represented any country in an International Event in an open category or has been included within any Registered Testing Pool or other whereabouts information pool maintained by any International Federation or National Anti-Doping Organization.

[Comment to Recreational Athlete: The term "open category" is meant to exclude competition that is limited to junior or age group categories.]

Regional Anti-Doping Organization: A regional entity designated by member countries to coordinate and manage delegated areas of their national anti-doping programs, which may include the adoption and implementation of anti-doping rules, the planning and collection of Samples, the management of results, the review of TUEs, the conduct of hearings, and the conduct of Educational programs at a regional level.

Registered Testing Pool: The pool of highest-priority *Athletes* established separately at the international level by International Federations and at the national level by *National Anti-Doping Organizations*, who are subject to focused *In-Competition* and *Out-of-Competition Testing* as part of that International Federation's or *National Anti-Doping Organization*'s test distribution plan and therefore are required to provide whereabouts information as provided in <u>Article 5.5</u> and the *International Standard* for *Testing* and Investigations.

Sample or Specimen: Any biological material collected for the purposes of Doping Control.

[Comment to Sample or Specimen: It has sometimes been claimed that the collection of blood Samples violates the tenets of certain religious or cultural groups. It has been determined that there is no basis for any such claim.]

Target Testing: Selection of specific Athletes for Testing based on criteria set forth in the International Standard for Testing and Investigations.

Technical Document: A document adopted and published by WADA from time to time containing mandatory technical requirements on specific anti-doping topics as set forth in an International Standard.

<u>TDSSA, Version 9.0 – 1 Jan 2023</u> Page 17/30



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

Testing: The parts of the *Doping Control* process involving test distribution planning, *Sample* collection, *Sample* handling, and *Sample* transport to the laboratory.

Use: The utilization, application, ingestion, injection or consumption by any means whatsoever of any *Prohibited Substance* or *Prohibited Method*.

WADA: The World Anti-Doping Agency.

10.2. Defined Terms from the 2021 International Standards that are used in the TDSSA are underlined.

<u>Athlete Passport Management Unit (APMU)</u>: A unit composed of a <u>Person</u> or <u>Persons</u> that is responsible for the timely management of the <u>Athlete Biological Passports</u> in <u>ADAMS</u> on behalf of the <u>Passport Custodian</u>.

<u>Doping Control Officer (or DCO)</u>: An official who has been trained and authorized by the <u>Sample Collection Authority</u> to carry out the responsibilities given to <u>DCOs</u> in the <u>International Standard</u> for <u>Testing</u> and Investigations.

<u>Doping Control Station</u>: The location where the <u>Sample Collection Session</u> will be conducted in accordance with Article 6.3.2. of the <u>International Standard</u> for <u>Testing</u> and <u>Investigations</u>.

<u>Further Analysis</u>: <u>Further Analysis</u>, as this term is used in the ISL, occurs when a <u>Laboratory</u> conducts additional analysis on an "A" <u>Sample</u> or a "B" <u>Sample</u> after an analytical result for that "A" <u>Sample</u> or that "B" <u>Sample</u> has been reported by the <u>Laboratory</u>.

[Comment: There is no limitation on a <u>Laboratory</u>'s authority to conduct repeat or confirmation analysis, or to analyze a Sample with additional <u>Analytical Methods</u>, or to perform any other type of additional analysis on an "A" Sample or "B" Sample prior to reporting an analytical result on that Sample. That is not considered <u>Further Analysis</u>. If a <u>Laboratory</u> is to conduct additional analysis on an "A" Sample or "B" Sample after an analytical result for that Sample has been reported (for example: additional Sample analysis to detect EPO, or GC/C/IRMS analysis, or analysis in connection with the Athlete Biological Passport or additional analysis on a stored Sample) it may do so after receiving approval from the <u>Testing Authority</u> or <u>Results Management Authority</u> (if different) or WADA. However, after an Athlete has been charged with a Code Article 2.1 anti-doping rule violation based on the presence of a Prohibited Substance, Metabolite(s) of a Prohibited Substance, or Marker(s) of the Use of a Prohibited Substance or Prohibited Method in a Sample, then <u>Further Analysis</u> on that Sample may only be performed with the consent of the Athlete or approval from a hearing body (see Code Article 6.5). <u>Further Analysis</u> may be performed by the same <u>Laboratory</u> that did the original Analytical Testing, or by a different Laboratory or other WADA-



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

approved laboratory, at the direction of the <u>Testing Authority</u> or <u>Results Management Authority</u> (if different) or WADA. Any other Anti-Doping Organization that wishes to conduct <u>Further Analysis</u> on a stored Sample may do so with the permission of the <u>Testing Authority</u> or <u>Results Management Authority</u> (if different) or WADA and shall be responsible for any follow-up Results Management. Any Sample storage or <u>Further Analysis</u> initiated by WADA or another Anti-Doping Organization shall be at WADA's or that Anti-Doping Organization's expense.]

<u>Laboratory</u>: A WADA-accredited laboratory applying <u>Test Methods</u> and processes to provide evidentiary data for the detection and/or identification of *Prohibited Substances* or *Prohibited Methods* on the *Prohibited List*, and if applicable, quantification of a <u>Threshold Substance</u> in <u>Samples</u> of urine and other biological matrices in the context of *Doping Control* activities.

<u>Major Event</u>: A series of individual international Competitions conducted together under an international multi-sport organization functioning as a ruling body (e.g., the Olympic Games, Pan American Games) and for which a significant increase of resources and capacity may be required to conduct *Doping Control* for the *Event*.

<u>Passport</u>: A collation of all relevant data unique to an individual *Athlete* that may include longitudinal profiles of *Markers*, heterogeneous factors unique to that particular *Athlete* and other relevant information that may help in the evaluation of *Markers*.

<u>Risk Assessment</u>: The assessment of risk of doping in a sport or sports discipline conducted by an *Anti-Doping Organization* in accordance with Article 4.2 of the *International Standard* for *Testing* and Investigations.

<u>Sample Collection Authority</u>: The organization that is responsible for the collection of <u>Samples</u> in compliance with the requirements of the <u>International Standard</u> for <u>Testing</u> and Investigations, whether (1) the <u>Testing Authority</u> itself; or (2) a <u>Delegated Third Party</u> to whom the authority to conduct <u>Testing</u> has been granted or sub-contracted. The <u>Testing Authority</u> always remains ultimately responsible under the <u>Code</u> for compliance with the requirements of the <u>International Standard</u> for <u>Testing</u> and Investigations relating to collection of <u>Samples</u>.

<u>Sample Collection Session</u>: All of the sequential activities that directly involve the *Athlete* from the point that initial contact is made until the *Athlete* leaves the <u>Doping Control Station</u> after having provided their <u>Sample(s)</u>.

<u>Technical Document for Sport Specific Analysis (TDSSA)</u>: The <u>Technical Document</u> which establishes minimum levels of analysis that <u>Anti-Doping Organizations</u> must apply to sports and sport disciplines for certain <u>Prohibited Substances</u> and/or <u>Prohibited Methods</u>, which are most likely to be abused in particular sports and sport disciplines.



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

<u>Test(s)</u>: Any combination of Sample(s) collected (and analyzed) from a single Athlete in a single Sample Collection Session.

<u>Test Distribution Plan</u>: A document written by an *Anti-Doping Organization* that plans <u>Testing on Athletes</u>, in accordance with the requirements of Article 4 of the <u>International Standard</u> for <u>Testing and Investigations</u>.

<u>Testing Authority</u>: The <u>Anti-Doping Organization</u> that authorizes <u>Testing</u> on <u>Athletes</u> it has authority over. It may authorize a <u>Delegated Third Party</u> to conduct <u>Testing pursuant</u> to the authority of and in accordance with the rules of the <u>Anti-Doping Organization</u>. Such authorization shall be documented. The <u>Anti-Doping Organization</u> authorizing <u>Testing remains</u> the <u>Testing Authority</u> and ultimately responsible under the <u>Code</u> to ensure the <u>Delegated Third Party</u> conducting the <u>Testing</u> does so in compliance with the requirements of the <u>International Standard</u> for <u>Testing</u> and <u>Investigations</u>.

10.3. Defined Terms Specific to the TDSSA

Minimum Level of Analysis (MLA): The number of analyses for the *Prohibited Substances* and/or *Prohibited Methods* within the scope of the <u>TDSSA</u> required to be performed by an *ADO* for each sport or discipline, expressed as a percentage of the total eligible Tests in their <u>TDP</u>.

Physiological Risk Assessment: Analysis of the physiological demands of a sport or discipline against the potential performance enhancing benefit of *Prohibited Substances* and/or *Prohibited Methods* on the <u>TDSSA</u>.



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

Appendix 1

Minimum Levels of Analysis for Sports and Disciplines of Olympic and IOC Recognized International Federations, and members of the Alliance of Independent Recognized Members of Sport

SPORT	DISCIPLINE	ERAs %	GH % ⁹⁶	GHRFs %
Aikido	Aikido	5	5	5
Air Sports	All	0	0	0
American Football	American Football	5	10 15	10 15
American Football	Flag Football	<u>5</u>	<u>5</u>	<u>5</u>
Aquatics	Diving	0	5	5
Aquatics	Swimming Sprint 100m or less	10	10	10
Aquatics	Swimming Long Distance 800m or greater	30	5	5
Aquatics	Swimming Middle Distance 200-400m	15	5	5
Aquatics	Open Water	30	5	5
Aquatics	Artistic Swimming	10	5	5
Aquatics	Water Polo	10	10	10
Archery	All	0	0	0
Arm Wrestling	Arm Wrestling	5	15	15
Athletics	Combined Events	15 10	15	15
Athletics	Jumps	10	15	15
Athletics	Long Distance 3000m or greater	60	5	5
Athletics	Middle Distance 800-1500m	30	10	10
Athletics	Sprint 400m or less	10	15	15
Athletics	Throws	5	15	15
<u>Athletics</u>	Trail and Mountain Running	<u>60</u>	<u>10</u>	<u>10</u>
Automobile Sports	All	5	0	0
Badminton	Badminton	10	10	10

⁹ The mandatory implementation of the GH MLAs for all sports/disciplines is postponed and will be assessed once the Endocrine Module of the *ABP* has been operational for at least one year.

¹⁰ The ERAs MLA will be increased to 30% in the TDSSA v10 that will come into effect on 1 January 2025. ADOs are encouraged to adjust their TDP to prepare for the revised ERAs MLA and the implementation of the Hematological Module of the ABP in this discipline.



Document number:	TDSSA	Version number:	<mark>89</mark> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 2022 16 November 2023	Effective date:	1 January 2023 2024

SPORT	DISCIPLINE	ERAs %	GH % ⁹⁶	GHRFs %
Bandy	Bandy	5	10	10
Baseball	Baseball	5	10	10
Basketball	Basketball	10	10	10
Basketball	3 on 3	10	10	10
Basque Pelota	Basque Pelota	5	5	5
Biathlon	Biathlon	60	10	10
Billiards Sports	All	0	0	0
Bobsleigh	Bobsleigh	5	10	10
Bobsleigh	Skeleton	0	10	10
Bodybuilding	Bodybuilding	5	30	30
Bodybuilding	Fitness	10	30	30
Boules Sports	All	0	0	0
Bowling	All	0	0	0
Boxing	Boxing	15	10	10
Bridge	Bridge	0	0	0
Canoe/Kayak	Sprint 200m	10	10	10
Canoe/Kayak	Canoe Slalom	15	10	10
Canoe/Kayak	Canoe Polo	5	10	10
Canoe/Kayak	Middle Distance 500m	15	10	10
Canoe/Kayak	Dragon Boat	10	5	5
Canoe/Kayak	Freestyle	5	10	10
Canoe/Kayak	Long Distance 1000m	30	5	5
Canoe/Kayak	Marathon	30	5	5
Canoe/Kayak	Ocean Racing	15 15 ¹⁰	5	5
Canoe/Kayak	Wildwater	5	10	10
Casting	Casting	0	0	0
Cheer	Cheer	5	5	5
Chess	Chess	0	0	0
Cricket	All	5	10	10
Curling	Curling	0	0	0
Cycling	Bike Handling Skills	5	5	5
Cycling	BMX Freestyle Park	5	10	10



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

SPORT	DISCIPLINE	ERAs %	GH % ⁹⁶	GHRFs %
Cycling	BMX Racing	5	15	15
Cycling	Cyclo-Cross	30	10	10
Cycling	Mountain Bike Downhill	5	10	10
Cycling	Mountain Bike Endurance	30	10	10
Cycling	Mountain Bike Sprint	5	15	15
Cycling	Road	60	10	10
Cycling	Track Endurance	30	10	10
Cycling	Track Sprint	5	15	15
Dance Sport	All	5	5	5
Darts	Darts	0	0	0
Dragon Boat	Dragon Boat	10	5	5
Draughts	Draughts	0	0	0
Equestrian	Dressage	0	0	0
Equestrian	Driving	0	0	0
Equestrian	Eventing	5	5	5
Equestrian	Endurance	5	5	5
Equestrian	Jumping	5	5	5
Equestrian	Reining	0	0	0
Equestrian	Vaulting	5	5	5
Fencing	Epee	5	5	5
Fencing	Foil	5	5	5
Fencing	Sabre	5	5	5
Field Hockey	Field Hockey	10	10	10
Field Hockey	Indoor	5	5	5
Fistball	Fistball	5	5	5
Floorball	Floorball	5	5	5
Flying Disc	Ultimate	5	5	5
Football	Beach Football	5	5	5
Football	Football	10	10	10
Football	Futsal	5	5	5
Go	Go	0	0	0
Golf	Golf	5	5	5



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 <u>2024</u>

SPORT	DISCIPLINE	ERAs %	GH % ⁹⁶	GHRFs %
Gymnastics	Artistic	10	10	10
Gymnastics	Acrobatic	5	10	10
Gymnastics	Rhythmic	5	5	5
Gymnastics	Aerobic	10	5	5
Gymnastics	Trampoline	5	5	5
Gymnastics	Tumbling	5	5	5
Handball	Beach	5	5	5
Handball	Indoor	10	10	10
Ice Hockey	Ice Hockey	5	10	10
Icestocksport	Icestocksport Target	0	0	0
Icestocksport	Icestocksport Distance	0	5	5
Ju-Jitsu	All	10	10	10
Judo	Judo	10	10	10
Karate	Karate	10	10	10
Kendo	Kendo	5	5	5
Kickboxing	All	15	10	10
Korfball	Korfball	10	5	5
Lacrosse	Lacrosse	10	10	10
LifeSaving	LifeSaving	10	5	5
Luge	Luge	0	10	10
Minigolf	Minigolf	0	0	0
Modern Pentathlon	Modern Pentathlon	5	5	5
Motorcycle Racing	All	5	0	0
Mountaineering and Climbing	All	10	5	5
Muaythai	Muaythai	15	10	10
Netball	Netball	10	5	5
Orienteering	All	15 15 ¹⁰	5	5
Polo	All	5	5	5
Powerboating	Aquabike	5	5	5
Powerboating	Circuit	0	0	0
Powerboating	Offshore	0	0	0
Powerlifting	All	5	30	30

<u>TDSSA, Version 9.0 – 1 Jan 2023</u> <u>Page 24/30</u>



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

SPORT	DISCIPLINE	ERAs %	GH % ⁹⁶	GHRFs %
Racquetball	Racquetball	10	5	5
Roller Sports	Alpine and Inline Downhill	10	10	10
Roller Sports	Artistic	5	5	5
Roller Sports	Hockey	5	10	10
Roller Sports	Inline Speed Skating Sprint 1000m or less	15	10	10
Roller Sports	Inline Speed Skating Distance greater than 1000m	30	10	10
Roller Sports	Roller Derby	5	5	5
Roller Sports	Roller Freestyle	5	10	10
Roller Sports	Scooter	5	10	10
Roller Sports	Skateboarding	5	10	10
Roller Sports	Skate-Cross	5	10	10
Rowing	Rowing	30	10	10
Rugby Union	Fifteens	10	10	10
Rugby Union	Sevens	10	10	10
Sailing	All	5	5	5
Sambo	Sambo	10	10	10
Savate	All	10	10	10
Sepaktakraw	All	0	0	0
Shooting	All	0	0	0
Skating	Figure Skating	10	10	10
Skating	Short Track	15	10	10
Skating	Speed Skating 1500m or less	15	10	10
Skating	Speed Skating greater than 1500m	30	10	10
Skating	Synchronized Skating	10	5	5
Skiing	Alpine	15	10	10
Skiing	Cross-Country	60	10	10
Skiing	Nordic Combined	30	10	10
Skiing	Freestyle (all subdisciplines)	10	5	5
Skiing	Ski Jumping	0	5	5
Skiing	Snowboard (all subdisciplines)	10	5	5
Ski Mountaineering	Ski Mountaineering	30	5	5
Sleddog	Sleddog	0	0	0

<u>TDSSA, Version 9.0 – 1 Jan 2023</u> <u>Page 25/30</u>



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 <u>2024</u>

SPORT	DISCIPLINE	ERAs %	GH % ⁹⁶	GHRFs %
Soft Tennis	Soft Tennis	5	5	5
Softball	Softball	5	10	10
Sport Climbing	Boulder	10	5 10	5 <u>10</u>
Sport Climbing	Combined	10	5 10	5 10
Sport Climbing	Lead	10	5 10	5 10
Sport Climbing	Speed	10	10	10
Sport Fishing	Sport Fishing	0	0	0
Squash	Squash	10	5	5
Sumo	Sumo	10	10	10
Surfing	All	10	5	5
Table Tennis	Table Tennis	5	5	5
Taekwondo	Poomsae	5	5	5
Taekwondo	Sparring	10	10	10
Tennis	Tennis	10	5	5
Teqball	Teqball	5	5	5
Triathlon	All	60	10	10
Tug of War	Tug of War	5	10	10
Underwater Sports	Aquathlon (Underwater Wrestling)	15	10	10
Underwater Sports	Finswimming Open Water	30	5	5
Underwater Sports	Finswimming Pool	15	5	5
Underwater Sports	Free Diving (all apnoea subdisciplines)	15	5	5
Underwater Sports	UW Orienteering	15	5	5
Underwater Sports	Spearfishing	15	5	5
Underwater Sports	Sport Diving	15	5	5
Underwater Sports	Target Shooting	0	0	0
Underwater Sports	UW Hockey	5	5	5
Underwater Sports	UW Rugby	5	5	5
Volleyball	Beach	5	5	5
Volleyball	Volleyball	5	5	5
Waterskiing	Barefoot	5	5	5
Waterskiing	Cable Wakeboard	5	5	5
Waterskiing	Cableski	5	5	5

<u>TDSSA, Version 9.0 – 1 Jan 2023</u> <u>Page 26/30</u>



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

SPORT	DISCIPLINE	ERAs %	GH % ⁹⁶	GHRFs %
Waterskiing	Racing Water Ski	5	5	5
Waterskiing	Tournament	5	5	5
Waterskiing	Wakeboard Boat	5	5	5
Weightlifting	Weightlifting	5	30	30
Wrestling	All	15	10	10
Wushu	Sanda	10	10	10
Wushu	Taolu	5	5	5

<u>TDSSA, Version 9.0 – 1 Jan 2023</u> <u>Page 27/30</u>



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

Appendix 2

Minimum Levels of Analysis for Sports and Disciplines of Athletes with an Impairment

IPC Sports

SPORT	DISCIPLINE	ERAs %	GH % ⁶⁸	GHRFs %
Para-Athletics	Wheelchair Racing - All Distances All Classes	30	10	10
Para-Athletics	Jumping - All Classes	5	10	10
Para-Athletics	Running Sprints 400m or less - All Classes	5	10	10
Para-Athletics	Running Middle Distance 800m - 1500m All Classes	15 15 ¹⁰	10	10
Para-Athletics	Running Endurance - greater than 1500m All Classes	30	5	5
Para-Athletics	Seated Throws - Classes: F31-F34/F51-F53	5	5	5
Para-Athletics	Seated Throws - Classes: F54-F57	5	10	10
Para-Athletics	Standing Throws - All Classes	5	10	10
Para-DanceSport	Para-DanceSport	0	0	0
Para-Ice Hockey	Para-Ice Hockey	5	5	5
Para-Powerlifting	Para-Powerlifting	5	30	30
Para-Swimming	Classes: S1/SB1/SM1-S3/SB3/SM3	5	5	5
Para-Swimming	Classes: S4/SB4/SM4-S9/SB8/SM9	15	5	5
Para-Swimming	Classes: S10/SB9/SM10-S14/SB14	30	10	10
Shooting Para Sport	Shooting Para Sport	0	0	0

<u>TDSSA, Version 9.0 – 1 Jan 2023</u> <u>Page 28/30</u>



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

Appendix 23

Non-IPC Sports

SPORT	DISCIPLINE	ERAs %	GH % ⁶⁸	GHRFs %
Archery	Para-Archery	0	0	0
Arm Wrestling	Para-Arm Wrestling	5	15	15
Badminton	Para-Badminton	5	5	5
Basketball	Wheelchair Basketball	5	5	5
Bobsleigh	Para-Bobsleigh	5	5	5
Boccia	Para-Boccia	0	0	0
Canoe	Para-Canoe	10	10	10
Curling	Wheelchair Curling	0	0	0
Cycling	Para-Cycling	30	5	5
Equestrian	Para-Equestrian	0	0	0
Fencing	Wheelchair Fencing	5	5	5
Field Hockey	Para-Field Hockey	5	5	5
Football 5-a-side	Para-Football 5-a-side	5	5	5
Football 7-a-side	Para-Football 7-a-side	5	5	5
Goalball	Goalball	5	5	5
Handball	Wheelchair Handball	5	5	5
Judo	Para-Judo	10	10	10
Rowing	Para-Rowing	30	10	10
Rugby	Wheelchair Rugby	5	5	5
Sailing	Para-Sailing	0	0	0
Para-Alpine Skiing	Para-Alpine Skiing	5	5	5
Para-Nordic Skiing	AllPara-Nordic Skiing	30	10	10
Para-SnowboardSkiing	Para-Snowboard	5	5	5
Sport Climbing	Para Climbing Lead	<u>5</u>	<u>10</u>	<u>10</u>
Surfing	Para Surfing (All subdisciplines)	<u>5</u>	<u>5</u>	<u>5</u>
ParaVolley	Sitting Volleyball	5	5	5
ParaVolley	Beach ParaVolley	5	5	5
Table Tennis	Para-Table Tennis	5	5	5
Taekwondo	Para-Taekwondo-Kyorugi	10	10	10
Tennis	Wheelchair Tennis	5	5	5



Document number:	TDSSA	Version number:	<u>89</u> .0
Written by:	Strategic Testing Expert Advisory Group	Approved by:	WADA Executive Committee
Date:	23 September 202216 November 2023	Effective date:	1 January 2023 2024

Triathlon	Para-Triathlon	30	10	10
Waterskiing	Disabled	0	0	0

<u>TDSSA, Version 9.0 – 1 Jan 2023</u> <u>Page 30/30</u>